GRIN2A and Parkinson disease: Targeting specific subunits of NMDA receptors, particularly GluN2A and GluN2B, through selective antagonism, has proven to be an effective approach in mitigating the pathological effects of excitotoxicity associated with the progression of neurodegenerative diseases like AD, Parkinson’s disease (PD), depression, and neuropathic pain [19,20].